What Flixabi Treats: Main Uses and Benefits

Flixabi is used in situations involving certain distressing symptoms associated with inflammatory conditions. This medication is applicable in conditions marked by episodic or fluctuating symptom patterns, such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, where symptoms create noticeable interference with daily functioning.

Easing Symptomatic Burden

Flixabi is used across domains where additional symptomatic support is needed, helping address symptom clusters that may become intense or disruptive during flare-ups. It is often used during phases when symptoms become more noticeable, offering supportive relief that helps ease the overall burden of symptoms and contributes to improved comfort during symptomatic periods. As the medicine is applied in clinical settings that involve acute or unstable symptom patterns, it is relevant when symptoms become momentarily overwhelming.

“It is applied in contexts marked by increased discomfort or tension.”

The use of Flixabi helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.

---

Quick Fact: Support for Heightened Physiological Stress

Official Population Eligibility Rules

Flixabi eligibility is strictly defined by regulatory authorities based on age, existing health conditions, and physiological status. The medicine is contraindicated and must not be used in several specific patient populations.

---

Eligibility Category	Regulatory Status
Absolute Contraindications	Patients with known severe infections (including active tuberculosis), moderate or severe heart failure (NYHA Class III/IV), or previous hypersensitivity to infliximab or murine proteins.
Adult Eligibility	Approved for use in adults (aged 18 years) across all labeled indications.
Pediatric Eligibility	Approved only for children and adolescents aged 6 to 17 years with severe Paediatric Crohn’s Disease or Paediatric Ulcerative Colitis. Use is not established for children under 6 years.
Pregnancy and Lactation	Not recommended during pregnancy unless clearly necessary. Breastfeeding is generally not recommended while the mother is receiving the medicine.
Organ Function	No specific dose adjustment is required for patients with renal or hepatic impairment.

---

Use is restricted in patients with mild heart failure (NYHA Class I/II), who require careful monitoring. Prior to initiating treatment, patients must be screened for latent tuberculosis to prevent reactivation.

Interactions with other medicines and products

Official regulatory documents define specific interaction constraints for Flixabi (Infliximab), particularly concerning immunosuppressive and biologic agents. Co-administration is not recommended with other biologic disease-modifying anti-rheumatic drugs (DMARDs) such as Anakinra or Abatacept. This restriction is due to an officially documented increased risk of serious infections and neutropenia, with no confirmed added benefit.

Contraindications and Administration Timing

The co-administration of Flixabi with live vaccines or therapeutic infectious agents is prohibited due to the immunosuppressive effect of Infliximab, which raises the risk of clinical infection. For infants exposed to Infliximab in utero, a waiting period of at least six months following birth is formally recommended before the administration of any live vaccine.

Pharmacokinetic and Pharmacodynamic Interactions

Concomitant use of the conventional immunosuppressant Methotrexate may lead to increased plasma concentrations of Infliximab. Furthermore, the official labeling notes that Flixabi's neutralization of TNF-α can potentially reverse the suppression of CYP450 enzymes caused by inflammation, which may alter the metabolism of other co-administered medicines that are CYP450 substrates. A population-specific caution exists for young male patients with inflammatory bowel disease receiving Flixabi combined with Azathioprine or 6-mercaptopurine, where an increased risk of Hepatosplenic T-cell Lymphoma (HSTCL) is documented.

---

Neutralizing the Primary Inflammatory Messenger

Flixabi's active mechanism centers on the neutralization of Tumor Necrosis Factor-alpha (TNF- alpha), a key protein associated with inflammatory signaling. By binding with high affinity to both the free-floating and cell-surface forms of TNF- alpha, the drug prevents it from reaching and activating its receptors. This molecular blockade is a foundational step that terminates the signal transduction pathway.

Blocking the Downstream Inflammatory Cascade

The blockade of TNF- alpha signaling leads to the inhibition of the entire downstream inflammatory cascade. This mechanism suppresses the activity of central transcription factors like NF-kappaB, which reduces the production and release of other inflammatory proteins such as IL-1 and IL-6. This systemic dampening results in the reduction of excessive inflammatory signaling within physiological pathways.

Active Removal of Immune Cells

Beyond simple signal suppression, the drug's antibody structure enables the targeted elimination of cells expressing cell-surface TNF- alpha through processes like Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC). This action decreases the cellular load expressing transmembrane TNF- alpha, which modulates subsequent tissue-level immune activity.

Flixabi is administered as an Intravenous (IV) Infusion only, and its use must be initiated and supervised by a qualified healthcare professional. The medicine is supplied as a sterile lyophilized powder (100 mg per vial) that must be carefully reconstituted and diluted before administration.

Administration Scope

Feature	Official Requirement
Route of Administration	Intravenous (IV) Infusion
Infusion Time	Not less than 2 hours (120 minutes)
Infusion Filter	Must use an in-line, sterile, low-protein-binding filter (le 1.2 mum)
Preparation Constraints	Infusion must begin within 3 hours of reconstitution/dilution

---

Standard Dosing Regimens

Flixabi dosing is calculated based on body weight (mg/kg) and follows a two-phase schedule.

Indication Type	Induction Dosing (Weeks 0, 2, 6)	Maintenance Dosing
Rheumatoid Arthritis (RA)	3 mg/kg	3 mg/kg every 8 weeks
Other Adult Indications (e.g., CD, UC, PsA, Ps)	5 mg/kg	5 mg/kg every 8 weeks
Ankylosing Spondylitis (AS)	5 mg/kg	5 mg/kg every 6 weeks
Pediatric (CD, UC, ge 6 years)	5 mg/kg	5 mg/kg every 8 weeks

For adult patients who initially respond but later lose response, the dose may be increased up to 10 mg/kg or, in the case of RA, the frequency may be increased to every 4 weeks, based on the approved product labeling.

Research Evidence / Overview of Studies for Flixabi

The research for Flixabi is centered on confirming its biosimilarity—meaning it has been rigorously demonstrated to be highly similar to the original reference medicine in terms of quality, function, and measured clinical outcomes. Regulatory bodies rely on a combination of studies, including direct comparison trials and a scientific principle called extrapolation, to support the scientific conclusion regarding the extrapolation of evidence to its approved uses.

---

Evidence for Use in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

The core research was conducted through Randomized Controlled Trials (RCTs) focusing primarily on Rheumatoid Arthritis (RA). These studies were designed to assess whether Flixabi's measured clinical and systemic profiles were equivalent to the reference medicine. In these trials, researchers monitored outcomes related to joint inflammation and daily functioning.

Studies reported that measured clinical response rates (e.g., ACR20) and drug concentration profiles fell within the predefined equivalence margins when compared to the reference product. For conditions like Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA), evidence is largely based on the scientific conclusion that similarity established in RA applies to these related conditions. Findings describe patterns observed in these studies, but comparative evidence for certain PsA sub-groups remains an area where data is still emerging.

---

Evidence for Use in Crohn's Disease and Ulcerative Colitis

The evidence related to the use of Flixabi in Crohn's Disease (CD) and Ulcerative Colitis (UC) is derived from the extrapolation of the rigorous biosimilarity findings established in the RA trials. This scientific conclusion is supported by the established scientific justification. Studies monitored how symptoms evolved in the observed populations during both the short-term induction phase and intermediate-term maintenance phases. Research has also explored outcomes in patients with CD presenting with certain disease characteristics.

---

Key Research Gaps and Remaining Uncertainty

While regulatory approval confirms high similarity, certain aspects remain under ongoing study. For instance, comparative evidence is lacking for direct head-to-head trials between Flixabi and all other available infliximab biosimilars. Furthermore, existing studies provide limited insight into the long-term clinical outcomes and patterns of harm reported in patients who frequently switch between different biosimilar products. Although the research is ongoing, results apply primarily to the specific populations studied, and data for certain difficult-to-treat groups remain insufficient.

Key Studies & References

1. Assessment of clinical similarity: an EU regulatory perspective on biosimilar development
2. NICE Guideline: Rheumatoid arthritis in adults: management (Includes guidance on biological DMARDs)
3. NICE Guideline: Crohn's disease: management (Includes guidance on biological therapies)

Common questions about Flixabi (FAQ)

---

Q: What are the inactive ingredients in Flixabi? Is it gluten-free or lactose-free?

A: Official product information, such as the Summary of Product Characteristics, lists the excipients (inactive ingredients) used in the formulation. These include sucrose, polysorbate 80 (E433), monobasic sodium phosphate monohydrate, and dibasic sodium phosphate heptahydrate. Regulatory documents confirm that the medicine does not contain gluten or lactose.

---

Q: What are the early signs that a person is having an infusion reaction?

A: Infusion reactions are documented adverse events that can occur during or soon after administration, or sometimes days later. The official product information states that signs can include general symptoms like fever and chills, or more serious signs such as chest pain, breathing difficulties, changes in blood pressure, or temporary changes in vision. Regulatory documents indicate that monitoring of patients occurs during and for a period following the administration of the infusion.

---

Q: How common is hair loss?

A: Regulatory documents list potential side effects according to how often they were reported in clinical studies. Hair loss, also known as alopecia, is classified as an uncommon side effect. This means it has been reported to affect up to 1 in 100 people treated with this medicine.

---

Q: How common are flu-like symptoms?

A: Flu-like symptoms are described in the official product information as an uncommon side effect. This classification means the reaction may affect up to 1 in 100 people, reflecting findings from clinical trials.

---

Q: What happens if an infusion is missed or delayed?

A: Regulatory information indicates that the safety and effectiveness of restarting treatment after a long break, specifically more than 16 weeks, has not been established. If maintenance therapy is interrupted and re-initiation is needed, regulatory documents state that repeating the induction regimen is not recommended. The prescribed approach involves a single dose followed by the original maintenance schedule.

---

Q: Does having a history of cancer contraindicate the use of Flixabi?

A: The Warnings and Precautions section in regulatory documents notes that use of this medicine may be associated with an increased risk of certain types of malignancy. A patient's history of cancer is a serious consideration, and official documentation requires that the potential risks and benefits are carefully assessed by the healthcare provider.

---

Q: Does Flixabi affect fertility in men or women?

A: Non-clinical studies, which examine the drug's effects in laboratory settings, did not show any direct or indirect harmful effects related to fertility. Official regulatory documents indicate that only limited data from human studies concerning fertility are currently available.

---

Q: What is the mechanism for loss of response over time?

A: Official product information on immunogenicity addresses why some patients may stop responding to treatment. The formation of anti-drug antibodies is noted as a potential factor. The formation of these antibodies may be associated with reduced effectiveness and a potential loss of clinical response.

---

Q: How quickly does Flixabi start to work?

A: Clinical efficacy data indicates that a clinical response has been observed within a specific timeframe, depending on the condition being treated. For example, studies suggest a clinical response is usually reached within about 12 weeks for rheumatoid arthritis or within 14 weeks for ulcerative colitis.

---

Q: Does the administration reason (e.g., Crohn's vs. RA) change the monitoring requirements?

A: General monitoring requirements, which include checks for serious risks like infection, heart failure symptoms, and Hepatitis B virus (HBV) reactivation, are consistently applied across all approved uses. The general safety monitoring requirements are noted to be consistent across various treated conditions.

---

Q: Can this drug be prescribed by a general practitioner or does it require a specialist?

A: Regulatory documents state that treatment must be started and supervised by qualified physicians who are specifically experienced in diagnosing and treating the diseases for which the medicine is indicated. This indicates the treatment requires supervision by a qualified physician experienced in the diagnosis and treatment of the specific indicated conditions.

How to Store and Dispose of Flixabi?

Storage Requirements (Unopened Vial)

The medicine must be stored in a refrigerator between 2 C and 8 C and kept in the original carton to protect it from light. The vial may be stored outside of refrigeration, up to 25 C, for a single period of up to six months, but not beyond the original expiry date. Once removed for ambient storage, the vial must not be returned to the refrigerator, and the new expiry date must be written on the carton.

Stability and Handling

It is recommended that the solution prepared for infusion is used as soon as possible (within three hours). Do not use the medicine if it is discoloured or if particles are present. The product must be kept out of the sight and reach of children.

Disposal

Do not use the medicine after the stated expiry date. Any unused medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.